Back
23
Day Range
$217.97
$225.03
52-Week Range
$204.90
$269.44
Volume
546,220
50D / 200D Avg
$246.93
/
$245.43
Prev Close
$221.00
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (627 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 35.4 | 0.3 |
| P/B | 3.3 | 2.9 |
| ROE % | 9.5 | 3.7 |
| Net Margin % | 11.3 | 3.8 |
| Rev Growth 5Y % | 15.1 | 10.0 |
| D/E | 0.3 | 0.2 |
Analyst Price Target
Hold
$256.67
+15.8%
Low: $245.00
High: $265.00
Forward P/E
21.7
Forward EPS
$10.20
EPS Growth (est.)
+0.0%
Est. Revenue
5.9 B
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2028 |
$12.26
$11.83 – $12.48
|
6.7 B | 5 |
| FY2027 |
$11.10
$10.85 – $11.27
|
6.3 B | 6 |
| FY2026 |
$10.20
$10.19 – $10.24
|
5.9 B | 6 |
Key Takeaways
Revenue grew 15.13% annually over 5 years — strong growth
Earnings grew 62.50% over the past year
Debt/Equity of 0.33 — conservative balance sheet
Generating 778.00M in free cash flow
P/E of 35.41 — premium valuation
PEG of 0.58 suggests growth is underpriced
Growth
Revenue Growth (5Y)
15.13%
Revenue (1Y)6.24%
Earnings (1Y)62.50%
FCF Growth (3Y)40.35%
Quality
Return on Equity
9.53%
ROIC7.38%
Net Margin11.26%
Op. Margin15.87%
Safety
Debt / Equity
0.33
Current Ratio1.96
Interest Coverage10.05
Valuation
P/E Ratio
35.41
P/B Ratio3.30
EV/EBITDA27.45
Dividend Yield0.01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 6.24% | Revenue Growth (3Y) | 9.71% |
| Earnings Growth (1Y) | 62.50% | Earnings Growth (3Y) | 139.64% |
| Revenue Growth (5Y) | 15.13% | Earnings Growth (5Y) | 11.52% |
| Profitability | |||
| Revenue (TTM) | 5.46B | Net Income (TTM) | 614.64M |
| ROE | 9.53% | ROA | 6.06% |
| Gross Margin | 44.01% | Operating Margin | 15.87% |
| Net Margin | 11.26% | Free Cash Flow (TTM) | 778.00M |
| ROIC | 7.38% | FCF Growth (3Y) | 40.35% |
| Safety | |||
| Debt / Equity | 0.33 | Current Ratio | 1.96 |
| Interest Coverage | 10.05 | Dividend Yield | 0.01% |
| Valuation | |||
| P/E Ratio | 35.41 | P/B Ratio | 3.30 |
| P/S Ratio | 3.99 | PEG Ratio | 0.58 |
| EV/EBITDA | 27.45 | Dividend Yield | 0.01% |
| Market Cap | 21.76B | Enterprise Value | 23.79B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 5.46B | 5.14B | 4.54B | 4.22B | 3.11B |
| Net Income | 614.64M | 378.24M | 107.03M | 243.89M | 397.40M |
| EPS (Diluted) | 6.20 | 3.81 | 1.07 | 2.48 | 4.63 |
| Gross Profit | 2.40B | 2.22B | 1.98B | 1.88B | 1.34B |
| Operating Income | 866.64M | 836.12M | 791.10M | 477.82M | 548.37M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 10.15B | 11.06B | 10.82B | 11.42B | 6.57B |
| Total Liabilities | 3.53B | 4.75B | 4.73B | 4.88B | 2.68B |
| Shareholders' Equity | 6.60B | 6.30B | 6.08B | 6.53B | 3.88B |
| Total Debt | 2.20B | 3.38B | 3.25B | 3.28B | 1.80B |
| Cash & Equivalents | 171.70M | 207.02M | 208.36M | 348.32M | 220.53M |
| Current Assets | 2.00B | 2.87B | 2.01B | 1.88B | 1.21B |
| Current Liabilities | 1.02B | 931.13M | 861.84M | 922.22M | 577.92M |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#943 of 1052
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026